These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25710707)

  • 21. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
    Ayyagari R; Wei W; Cheng D; Pan C; Signorovitch J; Wu EQ
    Value Health; 2015 Mar; 18(2):198-205. PubMed ID: 25773555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe.
    Graff MR; McClanahan MA
    Clin Ther; 1998; 20(3):486-96. PubMed ID: 9663364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nurses' perceptions and satisfaction with the use of insulin pen devices compared with insulin vial and syringes in an inpatient setting.
    Shogbon AO; Ngo D; Jacob B; Kimble LP; Ryan G
    Diabetes Technol Ther; 2014 Nov; 16(11):742-6. PubMed ID: 25198537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens.
    Brunton S
    Diabetes Technol Ther; 2008 Aug; 10(4):247-56. PubMed ID: 18715198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes.
    Buysman E; Conner C; Aagren M; Bouchard J; Liu F
    Curr Med Res Opin; 2011 Sep; 27(9):1709-17. PubMed ID: 21740289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
    Xie L; Zhou S; Wei W; Gill J; Pan C; Baser O
    Diabetes Technol Ther; 2013 Mar; 15(3):230-6. PubMed ID: 23336845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe.
    Stockl K; Ory C; Vanderplas A; Nicklasson L; Lyness W; Cobden D; Chang E
    Curr Med Res Opin; 2007 Jan; 23(1):133-46. PubMed ID: 17257475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of insulin delivery pen devices.
    Kroon L
    J Am Pharm Assoc (2003); 2009; 49(5):e118-31. PubMed ID: 19692314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes.
    Seggelke SA; Hawkins RM; Gibbs J; Rasouli N; Wang CC; Draznin B
    Endocr Pract; 2014 Jun; 20(6):536-9. PubMed ID: 24326004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin delivery with FlexPen: dose accuracy, patient preference and adherence.
    Pfützner A; Asakura T; Sommavilla B; Lee W
    Expert Opin Drug Deliv; 2008 Aug; 5(8):915-25. PubMed ID: 18713000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen.
    Ignaut DA; Schwartz SL; Sarwat S; Murphy HL
    Diabetes Educ; 2009; 35(5):789-98. PubMed ID: 19783767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benchmarking Insulin Treatment Persistence Among Patients with Type 2 Diabetes Across Different U.S. Payer Segments.
    Wei W; Jiang J; Lou Y; Ganguli S; Matusik MS
    J Manag Care Spec Pharm; 2017 Mar; 23(3):278-290. PubMed ID: 28230445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of insulin pen devices.
    McCoy EK; Wright BM
    Postgrad Med; 2010 May; 122(3):81-8. PubMed ID: 20463417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preference for insulin delivery systems among current insulin users and nonusers.
    Summers KH; Szeinbach SL; Lenox SM
    Clin Ther; 2004 Sep; 26(9):1498-505. PubMed ID: 15531012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
    Rashid N; McCombs JS; Schwartz E
    Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study.
    Haak T; Edelman S; Walter C; Lecointre B; Spollett G
    Clin Ther; 2007 Apr; 29(4):650-60. PubMed ID: 17617288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin devices: addressing barriers to insulin therapy with the ideal pen.
    Spollett G
    Diabetes Educ; 2008; 34(6):957-60, 963, 967. PubMed ID: 19075079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.
    Baser O; Bouchard J; DeLuzio T; Henk H; Aagren M
    Adv Ther; 2010 Feb; 27(2):94-104. PubMed ID: 20352392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.